Sign In
Buy ASND
$216.79
+0.190 (+0.0877%)
At Close: Jun 03, 2026
Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences
04:05pm, Wednesday, 21'st Apr 2021
COPENHAGEN, Denmark, April 21, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical need
Ascendis Pharma A/S Announces Participation at the J.P. Morgan 10th Annual Napa Valley Biotech Forum
07:05am, Tuesday, 30'th Mar 2021
COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidat
Clinical data demonstrate the potential of TransCon PTH as a hormone replacement therapy for adults with hypoparathyroidism Clinical data demonstrate the potential of TransCon PTH as a hormone replace
Ascendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare Conference
07:05am, Monday, 15'th Mar 2021
COPENHAGEN, Denmark, March 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidat
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q4 2020 Results - Earnings Call Transcript
04:03am, Thursday, 11'th Mar 2021
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q4 2020 Results - Earnings Call Transcript
Ascendis Pharma A/S Reports Full Year 2020 Financial Results
04:01pm, Wednesday, 10'th Mar 2021
– Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), continues on track –
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases
07:05am, Wednesday, 10'th Mar 2021
COPENHAGEN, Denmark, March 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical n
Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10
04:05pm, Thursday, 04'th Mar 2021
COPENHAGEN, Denmark, March 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidat
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021
07:05am, Friday, 26'th Feb 2021
COPENHAGEN, Denmark, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs
Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference
04:05pm, Thursday, 18'th Feb 2021
COPENHAGEN, Denmark, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidate
3 Companies With High Quality Balance Sheets to Consider
12:22pm, Wednesday, 10'th Feb 2021
If you screen the market for stocks that have a current ratio higher than 2 and more working capital than long-term debt, as Benjamin Graham, the pioneer of value investing, recommended, the chances t
Ascendis Pharma A/S Provides Vision 3x3 Update at 39th Annual J.P. Morgan Healthcare Conference
07:04pm, Sunday, 10'th Jan 2021
COPENHAGEN, Denmark, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidate
Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
07:39pm, Friday, 08'th Jan 2021
– Advances Vision 3x3 to extend global clinical and commercial reach –
Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference
07:05am, Monday, 04'th Jan 2021
COPENHAGEN, Denmark, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidate
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
04:05pm, Wednesday, 30'th Dec 2020
- TransCon TLR7/8 Agonist is designed for intratumoral, sustained release of resiquimod with minimal systemic exposure, while inducing a potent anti-tumor response -
